» Articles » PMID: 34900010

Mouse Pluripotent Stem Cell Differentiation Under Physiological Oxygen Reduces Residual Teratomas

Overview
Journal Cell Mol Bioeng
Publisher Springer
Date 2021 Dec 13
PMID 34900010
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Residual pluripotent stem cells (PSC) within differentiated populations are problematic because of their potential to form tumors. Simple methods to reduce their occurrence are needed.

Methods: Here, we demonstrate that control of the oxygen partial pressure (pO) to physiological levels typical of the developing embryo, enabled by culture on a highly oxygen permeable substrate, reduces the fraction of PSC within and the tumorigenic potential of differentiated populations.

Results: Differentiation and/or extended culture at low pO reduced measured pluripotency markers by up to four orders of magnitude for mouse PSCs (mPSCs). Combination with cell sorting increased the reduction to as much as six orders of magnitude. Upon implantation into immunocompromised mice, mPSCs differentiated at low pO either did not form tumors or formed tumors at a slower rate than at high pO

Conclusions: Low pO culture alone or in combination with other methods is a potentially straightforward method that could be applied to future cell therapy protocols to minimize the possibility of tumor formation.

Citing Articles

Depolymerizing F-actin accelerates the exit from pluripotency to enhance stem cell-derived islet differentiation.

Hogrebe N, Schmidt M, Augsornworawat P, Gale S, Shunkarova M, Millman J bioRxiv. 2024; .

PMID: 39484596 PMC: 11526947. DOI: 10.1101/2024.10.21.618465.


Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia.

Li Y, Younis D, He C, Ni C, Liu R, Zhou Y Front Endocrinol (Lausanne). 2024; 15:1439351.

PMID: 39279997 PMC: 11392723. DOI: 10.3389/fendo.2024.1439351.


Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead.

Grattoni A, Korbutt G, Tomei A, Garcia A, Pepper A, Stabler C Nat Rev Endocrinol. 2024; 21(1):14-30.

PMID: 39227741 DOI: 10.1038/s41574-024-01029-0.


Identification of unique cell type responses in pancreatic islets to stress.

Maestas M, Ishahak M, Augsornworawat P, Veronese-Paniagua D, Maxwell K, Velazco-Cruz L Nat Commun. 2024; 15(1):5567.

PMID: 38956087 PMC: 11220140. DOI: 10.1038/s41467-024-49724-w.


Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes.

Hogrebe N, Ishahak M, Millman J Cell Stem Cell. 2023; 30(5):530-548.

PMID: 37146579 PMC: 10167558. DOI: 10.1016/j.stem.2023.04.002.

References
1.
Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T . Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2012; 12(1):127-37. DOI: 10.1016/j.stem.2012.09.013. View

2.
Blum B, Bar-Nur O, Golan-Lev T, Benvenisty N . The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol. 2009; 27(3):281-7. DOI: 10.1038/nbt.1527. View

3.
Menendez S, Camus S, Herreria A, Paramonov I, Morera L, Collado M . Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency. Aging Cell. 2011; 11(1):41-50. DOI: 10.1111/j.1474-9726.2011.00754.x. View

4.
Hentze H, Soong P, Wang S, Phillips B, Putti T, Dunn N . Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res. 2009; 2(3):198-210. DOI: 10.1016/j.scr.2009.02.002. View

5.
Simon M, Keith B . The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol. 2008; 9(4):285-96. PMC: 2876333. DOI: 10.1038/nrm2354. View